|
**Overview**: ANCA MPO PR3 Panel**Introduction**: The ANCA MPO PR3 Panel is a diagnostic tool designed to screen for ANCA-specific antibodies using serum samples. In India, ANCA-associated vasculitis (AAV) is increasingly recognized as a cause of rapidly progressive glomerulonephritis and pulmonary-renal syndrome, with prevalence estimates of 10-20 per million population and higher in certain regions due to environmental triggers and genetic factors. MPO-ANCA and PR3-ANCA are key markers for microscopic polyangiitis and granulomatosis with polyangiitis respectively. Symptoms include hematuria, proteinuria, pulmonary hemorrhage, sinusitis, skin lesions, and renal failure. High morbidity from underdiagnosis in rural areas, limited rheumatology/nephrology access, overlap with tuberculosis/infections, and delayed immunosuppressive therapy leading to irreversible organ damage. Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for specific antibody detection over 1-2 days with high sensitivity/specificity, valuable for confirming ANCA vasculitis and guiding treatment. This diagnostic falls under autoimmune screening and targets individuals with suspected vasculitis, addressing accurate detection of MPO/PR3 antibodies to differentiate disease subtypes and initiate prompt therapy. With elevated morbidity due to underdiagnosis in resource-limited settings, the test supports public health efforts by enabling precise identification, facilitating management, and reducing mortality from renal/pulmonary complications. Its serum-based approach ensures reliable performance in India's diverse laboratory environments.**Other Names**: ANCA MPO PR3 Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Developed for specific ANCA detection; in India, prominence with rising vasculitis awareness in nephrology clinics.**Purpose**: The test screens for 2 parameters including MPO-ANCA and PR3-ANCA to guide vasculitis assessment, confirm autoimmune etiology, inform immunosuppressive treatment.**Test Parameters**: 1. MPO-ANCA, 2. PR3-ANCA.**Pretest Condition**: No fasting required; patients should report hematuria, proteinuria, pulmonary symptoms, sinusitis, or skin lesions.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on renal function, pulmonary symptoms, sinusitis, skin lesions, family autoimmune history, or recent infections.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated vasculitis including renal failure or pulmonary hemorrhage, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible ANCA vasculitis, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists or nephrologists should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: ANCA IFA, urine analysis, or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in limited disease or false positives in infections; comprehensive approach with clinical correlation required.**References**: Indian Journal of Rheumatology 2024, Vasculitis Studies India 2023. |
